Back to Journals » Neuropsychiatric Disease and Treatment » Call For Papers

Neuropsychiatric Disease and Treatment

ISSN: 1178-2021


The following Article Collections/ Thematic Series are currently open for submissions:

Cognitive dysfunction in bipolar disorder: Bio-psycho-social perspective

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Cognitive dysfunction in bipolar disorder: Bio-psycho-social perspective", organized by Guest Advisor Dr. Kuniyoshi Toyoshima in Neuropsychiatric Disease and Treatment.

Bipolar disorder affects >1% of the global population, and it causes cognitive impairment, functional disability, and death by suicide. Bipolar disorder is also characterized by recurring manic and depressive episodes. In individuals with bipolar disorder, not only mood symptoms but also cognitive impairment affects quality of life, even during euthymic phases and in the case of young people. Cognitive impairment also correlates with illness awareness, social function, suicidal ideation, etc. Therefore, recently, cognitive dysfunction has become considered to be a treatment target.

However, the pathology of cognitive impairment in bipolar disorder has not been elucidated. Furthermore, an effective treatment for cognitive dysfunction in bipolar disorder has not yet been established. Hence, in clinical settings, biological, psychological, and social interventions are performed in combination according to the patient’s condition.

This Article Collection seeks papers that study cognitive impairment in bipolar disorder, in terms of the bio-psycho-social perspective. It is hoped that this Article Collection will contribute to well-being and functional recovery in individuals with bipolar disorder.

Keywords:
• Cognitive dysfunction
• Bipolar disorder
• Functional recovery
• Well-being
• Bio-psycho-social perspective

All manuscripts submitted to this Article Collection will undergo desk assessment and peer-review as part of our standard editorial process. Guest Advisors for this collection will not be involved in peer-reviewing manuscripts unless they are an existing member of the Editorial Board. Please review the journal Aims and Scope and author submission instructions prior to submitting a manuscript.

The deadline for submissions is 31 March 2024.

Please submit your manuscript on our website, quoting the promo code QGCFU to indicate that your submission is for consideration in this Article Collection.

View all papers in this article collection

The effectiveness of non-pharmacological interventions for people with cognitive dysfunction

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "The effectiveness of non-pharmacological interventions for people with cognitive dysfunction", organized by Guest Advisors Professor Hsin-Hung Wu, Professor Pei-Fen Wu, and Dr. Kai-Ming Jhang in Neuropsychiatric Disease and Treatment.

There is no curable treatment for dementia. Strategies about how to prevent cognitive decline from the stages of subjective cognitive dysfunction or mild cognitive impairment into dementia are important. Appropriate care for people living with dementia (PLWD) and their caregivers, such as transferring suitable care facilities or communication skills according to their care needs, is also necessary.

The journal is seeking original submissions and review articles on the following topics related to the effectiveness of non-pharmacological intervention:
• Benefits of technological intervention in cognitive impairment: Technological intervention brings personalized, engaging, and innovative approaches to cognitive training, art therapy, reminiscence therapy, and social engagement and support. By leveraging technology, these interventions enhance cognitive functioning, stimulate creative expression, foster emotional well-being, and facilitate social connections, ultimately improve the overall quality of life for individuals.
• Assistive tools, devices, data analytics, and predictive models.
• The effectiveness of psychoeducation, behavioral therapy, multisensory therapy, therapeutic activities, individualized or group setting, on the change of cognitive function, behavior and psychological symptoms of dementia (BPSD) or physical function.
• The effectiveness of care models, such as specialized dementia units, collaborative care models, or case manager leading care coordination, on the change of cognitive function, BPSD or physical function.
• Benefits of different care facilities or care delivery systems on PLWD or their caregivers.

All manuscripts submitted to this Article Collection will undergo desk assessment and peer-review as part of our standard editorial process. Guest Advisors for this collection will not be involved in peer-reviewing manuscripts unless they are an existing member of the Editorial Board. Please review the journal Aims and Scope and author submission instructions prior to submitting a manuscript.

The deadline for submissions is 30 June 2024.

Please submit your manuscript on our website, quoting the promo code CPDTH to indicate that your submission is for consideration in this Article Collection.

View all papers in this article collection

Investigating the Role of Ketamine and Its Enantiomers in Bipolar Depression

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Investigating the Role of Ketamine and Its Enantiomers in Bipolar Depression", organized by Guest Advisor Dr. Alina Wilkowska in Neuropsychiatric Disease and Treatment

Bipolar depression (BD), affecting 2-3% of the global population, is a major research priority given the alarming suicide rates (5-10%) and a 30% non-response rate to existing treatments. The urgent need for innovative therapeutic strategies has led to interest in Ketamine and its enantiomers, including esketamine and arketamine, as potential options for BD treatment. However, robust evidence for ketamine's effectiveness in BD remains elusive, underscoring the necessity for thorough randomized studies, particularly those examining maintenance phase and long-term outcomes.

We invite submissions of original research and review articles exploring:

• Therapeutic strategies for BD focusing on ketamine, esketamine, and arketamine. Topics could include maintenance treatment, variability of formulations, co-administration with standard treatments such as lithium, and real-world data from patients with comorbidities on various medications.

• The impact of ketamine, esketamine, and arketamine on BD symptoms, including suicidality, anxiety, sleep disturbances, and anhedonia.

• The progression of BD as a chronic disease, contributing factors, and the potential roles of ketamine and its enantiomers in slowing this progression.

• Comprehensive reviews on definitions of treatment-resistant bipolar depression, offering insights into optimal definitions and categorizations.

• The influence of ketamine and its enantiomers on connectivity disturbances in BD, enhancing our understanding of their effects on brain network interactions.

• The role of ketamine and its enantiomers in addressing BD-associated immune system dysregulations. 

We welcome contributions from various disciplines aiming to advance our understanding of BD and the potential benefits of ketamine and its enantiomers. Please submit manuscripts in accordance with the guidelines provided on our journal's submission page. Together, let's strive to expand the therapeutic options for BD patients. 

All manuscripts submitted to this Article Collection will undergo desk assessment and peer-review as part of our standard editorial process. Guest Advisors for this collection will not be involved in peer-reviewing manuscripts unless they are an existing member of the Editorial Board. Please review the journal Aims and Scope and author submission instructions prior to submitting a manuscript.

The deadline for submissions is 31 March 2024.

Please submit your manuscript on our website, quoting the promo code YQCPB to indicate that your submission is for consideration in this Article Collection.

View all papers in this article collection

Current Insights into the Epidemiology, Risk Factors, Treatment and Management Options of Seizures and Epilepsy After Stroke

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Current Insights into the Epidemiology, Risk Factors, Treatment and Management Options of Seizures and Epilepsy After Stroke", organized by Guest Advisor Dr. Beata Sarecka-Hujar in Neuropsychiatric Disease and Treatment

Stroke is a serious medical problem resulting in several harmful neurological consequences which in both pediatric and adult patients affect everyday functioning and increase the costs of medical care and rehabilitation. Seizures and epilepsy are among the most common consequences of stroke although the incidence differs between the populations. Ischemic stroke is the cause of half of the epileptic seizures that newly occur in the population of patients above 60 years of age. Based on the time of onset of epileptic seizures after stroke, they can be divided into early (occurring up to 7 days after stroke) and late seizures (occurring up to 2 years after stroke), which are characterized by different pathomechanisms. 

It was reported that the mortality rate of stroke patients who experience poststroke seizures is significantly higher than that of all ischemic stroke patients. Moreover, it has been shown that seizures after stroke increase disability at discharge and also prolong hospital stay. In contrast, data on pediatric stroke patients have not shown increased mortality or disability in relation to early seizures. The available data may seem quite heterogeneous due to the definitions changing in recent years. Since 1.1 million patients suffer a stroke each year in Europe and poststroke survival rates improve, the number of patients with poststroke epilepsy continues to increase. In poststroke epilepsy, antiepileptic drug therapy is overall effective and monotherapy is sufficient in most patients, but there are still some treatment issues that require in-depth evaluation. Also, it remains difficult to assess the risk of poststroke seizures however some first attempts at predicting late seizures were demonstrated with promising results. Therefore, more detailed knowledge about risk factors for poststroke seizures and epilepsy and the ability to predict their occurrence may improve the prevention and treatment of the disease. 

The present Article Collection will focus on the current opinions on epidemiology, risk factors, classification and treatment as well as prognosis in poststroke seizures and epilepsy both in adults and children. This Collection will cover clinical cohort studies, studies on biomarkers, prospective and retrospective studies concerning epidemiology and treatment options, or neuroimaging studies. 

Keywords

  • Stroke
  • Poststroke Seizures
  • Epilepsy
  • Poststroke Consequences
  • Antiepileptic Treatment

All manuscripts submitted to this Article Collection will undergo desk assessment and peer-review as part of our standard editorial process. Guest Advisors for this collection will not be involved in peer-reviewing manuscripts unless they are an existing member of the Editorial Board. Please review the journal Aims and Scope and author submission instructions prior to submitting a manuscript. 

The deadline for submissions is 31 August 2024.

Please submit your manuscript on our website, quoting the promo code BQGZY to indicate that your submission is for consideration in this Article Collection.

Guest Advisor

Beata Sarecka-Hujar, Faculty of Pharmaceutical Sciences, Medical University of Silesia, Katowice, Poland

[email protected]

Beata Sarecka-Hujar, Ph.D. at the Medical University of Silesia in Katowice. Dr. Sarecka-Hujar conducts research on epidemiology, risk factors for cardiovascular diseases in adults as well as on risk factors and outcomes of neurological diseases, e.g. arterial ischemic stroke, epilepsy, schizencephaly, cerebral palsy in the paediatric population. Additionally, Dr. Sarecka-Hujar is interested in modern techniques for manufacturing and controlling pharmaceutical preparations. Dr. Sarecka-Hujar is a member of the Editorial Board of several journals, including BMC Pediatrics (Associate Editor), Brain Sciences, Journal of Pediatric Genetics, and Advanced Neurology. Dr. Sarecka-Hujar is an author of over 125 full-text articles, which can be found on ResearchGate or ORCID.

View all papers in this article collection

All about Psychogenic Non-Epileptic Seizures (PNES) and Functional Neurological Disorders (FND)

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "All about Psychogenic Non-Epileptic Seizures (PNES) and Functional Neurological Disorders (FND)", organized by Guest Advisor Dr. Daichi Sone in Neuropsychiatric Disease and Treatment

Psychogenic non-epileptic seizures (PNES), also known as a form of functional neurological disorders (FND), is a medically unexplained seizure disorder. PNES mimics epileptic seizures, but there is no evidence that they are caused by abnormal electrical activity in the brain like epilepsy, and it is generally supposed that they are caused by psychological factors. 

Although PNES is a common condition encountered in neuropsychiatric clinical practice, it is often misunderstood and misdiagnosed, leading to inappropriate treatments, such as unnecessary and harmful antiseizure medications for a long time. In addition, the gold standard for diagnosing PNES is video-EEG monitoring to record symptoms and EEG during PNES, but access to video-EEG monitoring varies widely from region to region, which is problematic. In addition, with appropriate treatment, such as rehabilitative and psychotherapeutic approaches, the prognosis for PNES is not necessarily poor, but the lack of a known mechanism of the disorder makes it difficult to develop a fundamental treatment. In recent years, it has attracted attention also in the field of neurology as a form of FND, and the neural mechanisms and the possibility of new treatments have been suggested. 

This Article Collection solicits papers, original research or review articles, on any aspect of PNES, including but is not limited to, psychosocial, clinical practice, psychiatric, neurological, and neuroscientific aspects; papers on conversion disorders other than PNES or other types of FND may also be considered. It is hoped that the review of the current state and novel discoveries will develop better clinical practice for PNES and FND. 

Keywords

  • Psychogenic Non-Epileptic Seizures (PNES)
  • Functional Neurological Disorders (FND)
  • Functional Seizures
  • Conversion Disorder
  • Epilepsy

All manuscripts submitted to this Article Collection will undergo desk assessment and peer-review as part of our standard editorial process. Guest Advisors for this collection will not be involved in peer-reviewing manuscripts unless they are an existing member of the Editorial Board. Please review the journal Aims and Scope and author submission instructions prior to submitting a manuscript. 

The deadline for submissions is 31 August 2024.

Please submit your manuscript on our website, quoting the promo code DPNSP to indicate that your submission is for consideration in this Article Collection.

Guest Advisor

Daichi Sone, Department of Psychiatry, Jikei University School of Medicine, Tokyo, Japan

[email protected]

After graduating from the University of Tokyo, Faculty of Medicine in 2008, Dr. Daichi Sone began his clinical career as a neuropsychiatrist through basic and specialized training. From 2012, he started working at National Center of Neurology and Psychiatry, Tokyo, Japan, specializing in neuropsychiatry, epileptology, and neuroimaging. He obtained PhD degree at Graduate School of Medicine, the University of Tokyo in 2017, and then, to develop the expertise in neuroimaging for epilepsy, he moved to London and launched the next career in Department of Clinical and Experimental Epilepsy, UCL Queen Square Institute of Neurology. Since 2021, Dr. Sone has been working at Department of Psychiatry, Jikei University School of Medicine, Tokyo, Japan, as a Senior Lecturer.

View all papers in this article collection


Call For Papers

Editor-in-Chief: Dr Roger M Pinder

To see where Neuropsychiatric Disease and Treatment is indexed online view the Journal Metrics

What is the advantage to you of publishing in Neuropsychiatric Disease and Treatment?

  • It is an open access journal which means that your paper is available to anyone in the world to download for free directly from the Dove website.
  • Although Neuropsychiatric Disease and Treatment receives a large number of papers, unlike many traditional journals, your paper will not be rejected due to lack of space. We are an electronic journal and there are no limits on the number or size of the papers we can publish.
  • The time from submission to a decision being made on a paper can, in many journals, take some months and this is very frustrating for authors. Neuropsychiatric Disease and Treatment has a quicker turnaround time than this. Generally peer review is complete within 3-4 weeks and the editor’s decision within 2-14 days of this. It is therefore very rare to have to wait more than 6 weeks for first editorial decision.
  • Many authors have found that our peer reviewer’s comments substantially add to their final papers.

To recover our editorial and production costs and continue to provide our content at no cost to readers we charge authors or their institution an article publishing charge.

PubMed Central
Neuropsychiatric Disease and Treatment is indexed on PubMed Central (title abreviation: Neuropsychiatr Dis Treat).  All published papers in this journal are submitted to PubMed for indexing straight away.

Become a Favored Author and receive real benefits
If you haven't already joined the Dove Press Favored Author Program I would encourage you to do so. Why? To receive real benefits like fast-tracking and a personal co-ordinator for your paper, as well as a discount on the publication processing fee.
Click here to go through to the Favored Author signup page.

Yours sincerely
Dr Roger M. Pinder
Editor-in-Chief
Neuropsychiatric Disease and Treatment

Email: Editor-in-Chief